T2	eligibility 317 398	patients with metastatic breast cancer pretreated with taxanes and anthracyclines
T3	total-participants 424 426	72
T1	intervention 23 35	capecitabine
T4	control 40 51	vinorelbine
T5	outcome 627 636	Responses
T6	iv-bin-abs 650 651	2
T7	intervention-participants 652 654	23
T8	iv-bin-percent 691 695	8.7%
T9	cv-bin-abs 718 719	3
T10	control-participants 720 722	24
T11	cv-bin-percent 758 763	12.5%
T12	outcome 783 815	Median progression-free survival
T13	iv-cont-median 820 823	2.8
T14	cv-cont-median 828 838	2.6 months
T15	outcome 844 867	median overall survival
T16	iv-cont-median 872 875	9.3
T17	cv-cont-median 880 891	11.0 months
T18	outcome 964 984	hematologic toxicity
T20	outcome 986 999	neurotoxicity
T21	outcome 1005 1020	nausea/vomiting
T19	outcome 1047 1055	diarrhea
T22	outcome 1060 1078	hand-foot syndrome
